Stati Uniti - inglese - NLM (National Library of Medicine)

endo pharmaceuticals, inc. - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan 6 mg in 0.5 ml

Canada - inglese - Health Canada

endo pharmaceuticals inc. - frovatriptan (frovatriptan succinate) - tablet - 2.5mg - frovatriptan (frovatriptan succinate) 2.5mg - selective serotonin agonists

Canada - inglese - Health Canada

endo pharmaceuticals inc. - frovatriptan (frovatriptan succinate) - tablet - 2.5mg - frovatriptan (frovatriptan succinate) 2.5mg - selective serotonin agonists

Stati Uniti - inglese - NLM (National Library of Medicine)

endo pharmaceuticals inc. - acrivastine (unii: a20f9xai7w) (acrivastine - unii:a20f9xai7w), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - acrivastine 8 mg - semprex-d capsules are indicated for relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion. semprex-d capsules should be administered when both the antihistaminic activity of acrivastine and the nasal decongestant activity of pseudoephedrine are desired (see clinical pharmacology ). the efficacy of semprex-d capsules beyond 14 days of continuous treatment in patients with seasonal allergic rhinitis has not been adequately investigated in clinical trials. semprex-d capsules have not been adequately studied for effectiveness in relieving the symptoms of the common cold. semprex-d capsules are contraindicated in patients with a known sensitivity to acrivastine, other alkylamine antihistamines (e.g., triprolidine), pseudoephedrine, other sympathomimetic amines (e.g., phenylpropanolamine), or to any other components of the formulation. semprex-d capsules are contraindicated in patients with severe hypertension or severe coronary arte

Stati Uniti - inglese - NLM (National Library of Medicine)

endo pharmaceuticals inc. - isosorbide dinitrate (unii: ia7306519n) (isosorbide dinitrate - unii:ia7306519n) - isosorbide dinitrate 40 mg - dilatrate® -sr sustained release capsules are indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of controlled-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. isosorbide dinitrate is contraindicated in patients who are allergic to it. do not use dilatrate® -sr in patients who are taking certain drugs for erectile dysfunction (phosphodiesterase inhibitors), such as sildenafil, tadalafil, vardenafil, or avanafil. concomitant use can cause severe hypotension, syncope, or myocardial ischemia. do not use dilatrate® -sr in patients who are taking the soluble guanylate cyclase stimulator riociguat. concomitant use can cause hypotension.

Stati Uniti - inglese - NLM (National Library of Medicine)

endo pharmaceuticals, inc. - frovatriptan succinate (unii: d28j6w18hy) (frovatriptan - unii:h82q2d5wa7) - frovatriptan 2.5 mg - frova is indicated for the acute treatment of migraine with or without aura in adults. limitations of use - use only if a clear diagnosis of migraine has been established. if a patient has no response for the first migraine attack treated with frova, reconsider the diagnosis of migraine before frova is administered to treat any subsequent attacks. use only if a clear diagnosis of migraine has been established. if a patient has no response for the first migraine attack treated with frova, reconsider the diagnosis of migraine before frova is administered to treat any subsequent attacks. - frova is not indicated for the prevention of migraine attacks. frova is not indicated for the prevention of migraine attacks. - safety and effectiveness of frova have not been established for cluster headache. safety and effectiveness of frova have not been established for cluster headache. frova is contraindicated in patients with: - ischemic coronary artery disease (cad) (e.g., angina pectoris, history of myocardial

Stati Uniti - inglese - NLM (National Library of Medicine)

endo pharmaceuticals, inc. - theophylline anhydrous (unii: 0i55128jyk) (theophylline anhydrous - unii:0i55128jyk) - theophylline anhydrous 100 mg - theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. theo-24 is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product.

Stati Uniti - inglese - NLM (National Library of Medicine)

endo pharmaceuticals inc. - methocarbamol (unii: 125od7737x) (methocarbamol - unii:125od7737x) - methocarbamol 500 mg - robaxin® and robaxin® -750 are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. the mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. methocarbamol does not directly relax tense skeletal muscles in man. robaxin® and robaxin® -750 are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

Canada - inglese - Health Canada

novartis pharmaceuticals canada inc - inclisiran (inclisiran sodium) - solution - 284mg - inclisiran (inclisiran sodium) 284mg

Stati Uniti - inglese - NLM (National Library of Medicine)

bryant ranch prepack - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - endocet is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.  limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve endocet for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia endocet is contraindicated in patients with: - significant respiratory depression [see warnings ] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings ] - known or suspected gastrointestinal obstruction, including paralytic ileus [see warnings ] - hypersensitivity to oxycodone, acetaminophen, or any other component of the product (e.g., anaphylaxis) [see warnings , adverse reactions ] endocet contains oxycodone, a